Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

375results about "Cationic antimicrobial peptides" patented technology

Polyvalent multimeric composition containing active polypeptides, pharmaceutical compositions and methods of using the same

The invention is directed to compositions comprising polyvalent complexes containing a biocompatible polymer backbone to which is attached a plurality of monomeric anti-microbial peptides and to methods for using such complexes to stabilize anti-microbial peptides for treating or preventing a disease or condition resulting from infection with a microbe. Multivalent derivatives of existing antimicrobial peptides in which several peptides are covalently linked have been investigated. The resulting construct may contain up to 30 or more units, and exhibits a significant enhancement of anti-microbial effect relative to the free peptides: on the order of a ten fold improvement in effectiveness, suggesting that higher multimerization can indeed lead to more effective agents. The invention is also directed to the use of such complexes for delivery of anti-viral peptides, in particular, peptides and peptide fragments obtained from salivary agglutinin protein (gp-340) for use in treating or preventing infection with HIV.
Owner:NEW YORK UNIV

Blockade Of Inflammatory Proteases With Cyclic Peptides

ActiveUS20130157964A1Mitigation of lethalityInhibit pro-inflammatory cytokines/chemokinesNervous disorderAntipyreticCyclic peptideAutoimmune responses
Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a θ-defensin, analog or derivative thereof. Inventive methods include researching θ-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) or other proinflammatory proteases, and / or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products